RBM4 and lung carcinoma: Overall, our results elucidate a novel mechanism of how nuclear AURKA regulates m6A reader YTHDC1-mediated RBM4 aberrant splicing, and provide therapeutic opportunities for lung cancer by targeting nuclear translocation of AURKA.